Trump Impact on Medicare Drug Price Negotiations Uncertain
Trump has reversed some of President Biden’s initiatives, including $2 monthly out-of-pocket cap on some generics and experimental pricing models for gene therapies. But so far the healthcare elements of the Inflation Reduction Act remain unchanged.
In November, a federal judge ordered CMS to recalculate UnitedHealthcare's Medicare Advantage Star Ratings for the 2025 plan ...
Federal health agencies, including the Centers for Medicare & Medicaid Services, have halted their communication efforts in ...
Transparency in the program is more than just a mechanism for fair pricing—it is a driving force that diminishes the returns ...
'The IRA's drug price controls are already hindering investment in critical drug research and development, undermining the innovation that has long made the U.S. a global leader in biopharmaceutical ...
Final rule makes it easier for CMS to suspend agents and brokers who exchange plans without notifying the Medicare customer.
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare ...
The Maryland Department of Health has received approval from the Centers for Medicare and Medicaid Services (CMS) for two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback